Eiger BioPharmaceuticals, Inc. Overview
Pro stress-test →Eiger BioPharmaceuticals is a biopharmaceutical company focused on developing therapies for rare and ultra-rare diseases, particularly Hepatitis Delta Virus (HDV) infection and rare metabolic disorders. The company filed for Chapter 11 bankruptcy in April 2024, significantly impacting its operational and financial status.
Strategic Profile
Pro stress-test →Prior to bankruptcy, Eiger positioned itself as a commercial-stage biotech with lonafarnib (Zokinvy) as its lead candidate for HDV and progeria-related diseases. The company's pipeline included avexitide for post-bariatric hypoglycemia, though the asset was sold during bankruptcy proceedings (April 2024 to Amylyx Pharmaceuticals). The company operates in a competitive rare disease space against specialized biotechs focused on orphan indications.
Competitive Landscape
Pro stress-test →Eiger competes in the rare metabolic disease and orphan indication space against specialized biotechs including Ultragenyx Pharmaceutical, Fibrocell Science, and other rare disease-focused developers. The HDV treatment market remains relatively underpenetrated with limited competitors; however, Eiger's bankruptcy status and operational constraints significantly limit competitive positioning. Partnership with AnGes in Japan provides regional differentiation for Zokinvy.
Industry Context
Eiger BioPharmaceuticals, Inc. operates in Biotechnology - Rare/Orphan Diseases.
Key facts
Founded: 2008 · Headquarters: Palo Alto, US · Employees: N/A · Revenue: N/A · Market cap: $12.59M